Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fortin

Showing results (141-150 of 329) with videos related to

Pageof 33
Sort By:
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1987
L-648,051: an aerosol active leukotriene D4 receptor antagonistT R Jones, Y Guindon, E Champion, et al.
Molecular Pharmacology|July 1, 1991
5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitorsJ F Evans, C Lévillé, J A Mancini, et al.
European Journal of Pharmacology|March 17, 1987
Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonistR A Hall, J Gillard, Y Guindon, et al.
Canadian Journal of Physiology and Pharmacology|June 1, 1992
Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitorC Brideau, C Chan, S Charleson, et al.
The Journal of Molecular Diagnostics : JMD|March 1, 2011
Molecular markers of injury in kidney biopsy specimens of patients with lupus nephritisHeather N Reich, Carol Landolt-Marticorena, Paul C Boutros, et al.
Journal of Autoimmunity|February 14, 2015
Interferon-α induces altered transitional B cell signaling and function in Systemic Lupus ErythematosusNan-Hua Chang, Timothy T Li, Julie J Kim, et al.
The Journal of Rheumatology|June 3, 2010
Altered expression of TNF-alpha signaling pathway proteins in systemic lupus erythematosusLang-Jing Zhu, Carolina Landolt-Marticorena, Timothy Li, et al.
The Journal of Rheumatology|March 3, 2005
Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspectiveBruno Fautrel, Ann E Clarke, Francis Guillemin, et al.
Frontiers in Immunology|May 29, 2019
Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNAYann Becker, Geneviève Marcoux, Isabelle Allaeys, et al.
Journal of Medicinal Chemistry|September 1, 1986
Design and synthesis of sodium (beta R*, gamma S*)-4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl] thio]-gamma-hydroxy-beta-methylbenzenebutanoate: a novel, selective, and orally active receptor antagonist of leukotriene D4R N Young, P Bélanger, E Champion, et al.
Pageof 33

Showing results (141-150 of 329) with videos related to

Sort By:
Pageof 33
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1987
L-648,051: an aerosol active leukotriene D4 receptor antagonistT R Jones, Y Guindon, E Champion, et al.
Molecular Pharmacology|July 1, 1991
5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitorsJ F Evans, C Lévillé, J A Mancini, et al.
European Journal of Pharmacology|March 17, 1987
Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonistR A Hall, J Gillard, Y Guindon, et al.
Canadian Journal of Physiology and Pharmacology|June 1, 1992
Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitorC Brideau, C Chan, S Charleson, et al.
The Journal of Molecular Diagnostics : JMD|March 1, 2011
Molecular markers of injury in kidney biopsy specimens of patients with lupus nephritisHeather N Reich, Carol Landolt-Marticorena, Paul C Boutros, et al.
Journal of Autoimmunity|February 14, 2015
Interferon-α induces altered transitional B cell signaling and function in Systemic Lupus ErythematosusNan-Hua Chang, Timothy T Li, Julie J Kim, et al.
The Journal of Rheumatology|June 3, 2010
Altered expression of TNF-alpha signaling pathway proteins in systemic lupus erythematosusLang-Jing Zhu, Carolina Landolt-Marticorena, Timothy Li, et al.
The Journal of Rheumatology|March 3, 2005
Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspectiveBruno Fautrel, Ann E Clarke, Francis Guillemin, et al.
Frontiers in Immunology|May 29, 2019
Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNAYann Becker, Geneviève Marcoux, Isabelle Allaeys, et al.
Journal of Medicinal Chemistry|September 1, 1986
Design and synthesis of sodium (beta R*, gamma S*)-4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl] thio]-gamma-hydroxy-beta-methylbenzenebutanoate: a novel, selective, and orally active receptor antagonist of leukotriene D4R N Young, P Bélanger, E Champion, et al.
Pageof 33